Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gynecologic Oncology
•
Ovarian Cancer
How would you approach a pre-viable pregnant patient in the second trimester with metastatic ovarian cancer and wants to keep the pregnancy?
Related Questions
What are your top takeaways in Gyn Cancers from ESMO 2024?
Would you recommend surgery or stereotactic radiation therapy for a young woman with high-grade serous ovarian cancer presenting with a pelvic LN oligometastasis following maintenance therapy?
How would you approach a patient who is unable to undergo the recommended ophthalmologic examinations during treatment with mirvetuximab soravtansine?
How do you factor a decreasing but persistently elevated CA-125 into your decision regarding whether to proceed with interval cytoreductive surgery for PAX8+ high-grade serous cancer s/p neoadjuvant chemotherapy with minimal disease on imaging?
Would you favor giving mirvetuximab before paclitaxel/bevacizumab?
Have you had patients who wish to take ivermectin and/or fenbendazole as adjunct treatments for gynecologic cancers and if so, how have you handled this?
For patients with ovarian cancer, do you order folate receptor-alpha testing at initial diagnosis, first recurrence, or first instance of platinum resistance?
When prescribing bevacizumab for high-risk primary ovarian cancer, do you use 15 mg/m2 q 21 days (per GOG-0218) or 7.5 mg/m2 q 21 days (per ICON7)?
How does your management and counseling of a patient with ovarian cancer change when they have significant persistent disease after neoadjuvant chemotherapy?
How do you manage patients with germline BRCA mutations who have STIC lesions found at the time of risk-reducing BSO?
